Autologous Plasma Enriched with Platelet Lysate for the Treatment of Idiopathic Age-Related Macular Degeneration: A Prospective Study

Cover Page
  • Authors: Lykov A.P.1,2, Poveshchenk O.V.1,2, Surovtseva M.A.1,2, Stanishevskaya O.M.3, Chernykh D.V.3, Arben’eva N.S.3, Bratko V.I.3
  • Affiliations:
    1. Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
    2. Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation
    3. S. Fyodorov Eye Microsurgery Federal State Institution
  • Issue: Vol 73, No 1 (2018)
  • Pages: 40-48
  • Section: OPHTHALMOLOGY: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/932
  • DOI: https://doi.org/10.15690/vramn932

Abstract


Background: Plasma enriched in growth factors is widely used in medical practice. However, the clinical efficacy of its application in the treatment of age-related retinal integrity violations is investigated insufficiently. 

Aims: The aim of the study was to evaluate the clinical efficacy of autologous plasma enriched with platelet lysate for treating age-related macular degeneration. 

Materials and methods: A three-port subtotal transconjunctival vitrectomy was performed and administration of the autologous plasma enriched with platelet lysate was indicated. Autologous plasma enriched with platelet lysate was received from the peripheral blood. We assessed visual acuity, intraocular pressure; conducted optical coherent tomography examination of the eye on the side of the pathological process. 

Results: The study demonstrated that the combination of a standard 3-port transconjunctival subtotal vitrectomy followed by tamponade of the gap using the autologous plasma enriched with platelet lysate with the injections of the autologous plasma enriched with platelet lysate in the area of pterygopalatine fossa on the side of the operated eyes statistically significantly promoted recovery of the visual acuity in the early postoperative period (15 days) and late period (90 days) if compared with patients who received only surgical treatment (p≤0.05). Use of the autologous plasma enriched with platelet lysate in the treatment increased the closing rate of the tearing of the retina in the macular region up to 62,5%, while only surgical treatment leads to the closure of the defect of the retina in 37.5% of cases. The study showed that autologous plasma enriched with platelet lysate contains cytokines, growth factors, and nitric oxide which are involved in the regeneration/reparation of the retina. 

Conclusions: Additional administration of the autologous plasma enriched with platelet lysate in the scheme of treatment patients with age-related macular degeneration is accelerating the closure of retinal tears of the eye and improves visual acuity.


A. P. Lykov

Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences;
Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation

Author for correspondence.
Email: aplykov2@mail.ru
ORCID iD: 0000-0003-4897-8676

Russian Federation Novosibirsk

O. V. Poveshchenk

Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences;
Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation

Email: mfelde@ngs.ru
ORCID iD: 0000-0002-4752-988X

Russian Federation Novosibirsk

M. A. Surovtseva

Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences;
Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation

Email: poveshchenkoov@yandex.ru
ORCID iD: 0000-0001-9956-0056

Russian Federation Novosibirsk

O. M. Stanishevskaya

S. Fyodorov Eye Microsurgery Federal State Institution

Email: stanishevskaya.olya@gmail.com
ORCID iD: 0000-0002-4149-3767

Russian Federation Novosibirsk

D. V. Chernykh

S. Fyodorov Eye Microsurgery Federal State Institution

Email: nfmntk.dima@gmail.com
ORCID iD: 0000-0003-0151-2596

Russian Federation Novosibirsk

N. S. Arben’eva

S. Fyodorov Eye Microsurgery Federal State Institution

Email: daisy5555@yandex.ru
ORCID iD: 0000-0003-1066-0339

Russian Federation Novosibirsk

V. I. Bratko

S. Fyodorov Eye Microsurgery Federal State Institution

Email: anest0592@gmail.com
ORCID iD: 0000-0002-1705-9944

Russian Federation Novosibirsk

  1. Егоров Е.А. Некоторые аспекты патогенеза и лечения возрастной макулярной дегенерации // Русский медицинский журнал. Клиническая офтальмология. ― 2016. ― №1 ― С. 46–49. [Egorov EA. Nekotorye aspekty patogeneza i lecheniya vozrastnoi makulyarnoi degeneratsii. RMJ. Klinicheskaya oftal’mologiya. 2016;(1):46−49. (In Russ).]
  2. who.int [Internet]. Global data on visual impairments 2010 [cited 2018 Jan 15]. Available from: http://www.who.int/blindness/GLO-BALDATAFINALforweb.pdf.
  3. Фихман О.З., Трофимова С.В. Современная тактика лечения возрастной макулодистрофии // Успехи геронтологии. ― 2004. ― Т.15. ― №15 ― С. 115–118. [Fikhman OZ, Trofimova SV. Current tactics of age-related macular degeneration treatment. Adv Gerontol. 2004;15(15):115−118. (In Russ).]
  4. Муха А.И., ЛысенкоВ.С., Галилеева В.В. и др. Гемокомпонентная терапия центральной инволюционной хориоретинальной дистрофии // Вестник офтальмологии. ― 1998. ― Т.114. ― №1 ― С. 28–31. [Mukha AI, Lysenko VS, Galileeva VV, et al. Hemocomponent therapy of central involution chorioretinal dystrophy. Vestn Oftalmol. 1998;114(1):28−31. (In Russ).]
  5. Figueroa MS, Nadal J, Contreras I. A rescue therapy for persistent optic disk pit maculopathy in previously vitrectomized eyes. Retin Cases Brief Rep. 2018;12(1):68–74. doi: 10.1097/ICB.0000000000000416.
  6. Todorich B, Sharma S, Vajzovic L. Successful repair of recurrent optic disk pit maculopathy with autologous platelet rich plasma: report of a surgical technique. Retin Cases Brief Rep. 2017;11(1):15–17. doi: 10.1097/ICB.0000000000000276.
  7. Захаров В.Д., Айрапетова Л.Э. Способ хирургического лечения отслоек сетчатки с макулярным разрывом. Патент RU 2103377 C1. Опубл. 27.11.2002. [Patent RUS 2103377 C1/ 27.11.02. Zakharov VD, Airapetova LE. Sposob khirurgicheskogo lecheniya otsloek setchatki s makulyarnym razryvom. (In Russ).]
  8. Бибков М.М., Алтынбаев У.Р., Абсаликов А.В. Способ лечения макулярного разрыва, осложненного отслойкой сетчатки и центральной хориоретинальной дегенерацией. Патент RU 2367391 С1. Опубл. 20.09.2009. [Patent RUS 2367391 C1/ 20.09.09. Bibkov MM, Altynbaev UR, Absalikov AV. Sposob lecheniya makulyarnogo razryva, oslozhnennogo otsloikoi setchatki i tsentral’noi khorioretinal’noi degeneratsiei. (In Russ).]
  9. Уласевич О.А. Способ хирургического лечения макулярных разрывов. Патент RU 2391953 С1. Опубл. 20.06.2010. [Patent RUS 2391953 C1/ 20.06.10. Ulasevich OA. Sposob khirurgicheskogo lecheniya makulyarnykh razryvov. (In Russ).]
  10. Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of “eye platelet rich plasma” (E-PRP) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012;13(7):1257–1265. doi: 10.2174/138920112800624355.
  11. Limoli PG, Limoli C, Vingolo EM, et al. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016;7(30):46913–46923. doi: 10.18632/oncotarget.10442.
  12. Geremicca W, Fonte C, Vecchio S. Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms. Blood Transfusion. 2010;8(2):107–112.
  13. Лыков А.П., Бондаренко Н.А., Суровцева М.А., и др. Сравнительный эффект обогащенной тромбоцитами плазмы, лизата тромбоцитов и эмбриональной телячьей сыворотки на мезенхимные стволовые клетки // Бюллетень экспериментальной биологии и медицины. ― 2017. ― Т.163. ― №6 ― С. 722−725. [Lykov AP, Bondarenko NA, Surovtseva MA, et al. Comparative effects of platelet-rich plasma, platelet lysate, and fetal calf serum on mesenchymal stem cells. Bull Exp Biol Med. 2017;163(6):757−760. (In Russ).]
  14. Lykov AP, Bondarenko NA, Poveshchenko OV, et al. Biomedical cellular product for wound healing. Integr Obesity Diabetes. 2015;2(1):176–179. doi: 10.15761/iod.1000139.
  15. Kobayashi Y, Saita Y, Nishio H, et al. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016;21(5):683–689. doi: 10.1016/j.jos.2016.07.009.
  16. Pezzotta S, Del Fante C, Scudeller L, et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant. 2012;47(12):1558–1563. doi: 10.1038/bmt.2012.64.
  17. Valentini CG, Nuzzolo ER, Orlando N, et al. Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease. Vox Sang. 2016;110(2):189–192. doi: 10.1111/vox.12325.
  18. Anitua E, Troya M, Zalduendo M, Orive G. Personalized plasma-based medicine to treat age-related diseases. Mater Sci Eng C Mater Biol Appl. 2017;74:459–464. doi: 10.1016/j.msec.2016.12.040.
  19. Márquez-de-Aracena R, Montero-de-Espinosa I, Muñoz M, Pereira G. [Subconjunctival application ofplasmaplateletconcentrate in the treatment of ocular burns. Preliminary results. (In Spanish).] Arch Soc Esp Oftalmol. 2007;82(8):475−481.
  20. Ronci C, Ferraro AS, Lanti A, et al. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfus Apher Sci. 2015;52(3):300–304. doi: 10.1016/j.transci.2014.12.027.
  21. Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol. 2012;56(6):544–550. doi: 10.1007/s10384-012-0175-y.
  22. Konstantinidis A, Hero M, Nanos P, Panos GD. Efficacy of autologous platelets in macular hole surgery. Clin Ophthalmol. 2013;7:745–750. doi: 10.2147/OPTH.S44440.
  23. Koh HH, Murray IJ, Nolan D, et al. Plasma and macular response to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res. 2004;79(1):21–27. doi: 10.1016/j.exer.2004.03.001.
  24. Karel I, Kalvodova B, Dotrelova D, et al. Vitrectomy and autologous thrombocyte concentrate in the treatment of idiopathic macular holes. Cesk Slov Oftalmol. 1999;55(4):191–202.
  25. Anitua E, Muruzabal F, De la Fuente M, et al. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res. 2014;119:27–34. doi: 10.1016/j.exer.2013.12.005.
  26. Evanson JR, Guyton MK, Oliver DL, et al. Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med. 2014;179(7):799–805. doi: 10.7205/milmed-d-13-00336.
  27. Sergeeva NS, Shanskii YD, Sviridova IK, et al. Analysis of reparative activity of platelet lysate: effect on cell monolayer recovery in vitro and skin wound healing in vivo. Bull Exp Biol Med. 2016;162(1):138–145. doi: 10.1007/s10517-016-3563-3.
  28. Sandri G, Bonferoni MC, Rossi S, et al. Thermosensitive eye drops containing plateletlysatefor the treatment of corneal ulcers. Int J Pharm. 2012 Apr 15;426(1−2):1−6. doi: 10.1016/j.ijpharm.2011.12.059.

Views

Abstract - 7

PDF (Russian) - 4

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.